JP2018531269A - 脂肪由来幹細胞に基づく幹細胞治療 - Google Patents

脂肪由来幹細胞に基づく幹細胞治療 Download PDF

Info

Publication number
JP2018531269A
JP2018531269A JP2018520404A JP2018520404A JP2018531269A JP 2018531269 A JP2018531269 A JP 2018531269A JP 2018520404 A JP2018520404 A JP 2018520404A JP 2018520404 A JP2018520404 A JP 2018520404A JP 2018531269 A JP2018531269 A JP 2018531269A
Authority
JP
Japan
Prior art keywords
cells
asc
composition
cell
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018520404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531269A5 (https=
JP2018531269A6 (ja
Inventor
イェンス・カストルプ
アネット・エクブロン
マンダナ・ハーク−セレンセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigshospitalet
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Publication of JP2018531269A publication Critical patent/JP2018531269A/ja
Publication of JP2018531269A6 publication Critical patent/JP2018531269A6/ja
Publication of JP2018531269A5 publication Critical patent/JP2018531269A5/ja
Priority to JP2022031113A priority Critical patent/JP2022084665A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C12N2500/62—DMSO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2018520404A 2015-10-23 2016-10-21 脂肪由来幹細胞に基づく幹細胞治療 Pending JP2018531269A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022031113A JP2022084665A (ja) 2015-10-23 2022-03-01 脂肪由来幹細胞に基づく幹細胞治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15191213 2015-10-23
EP15191213.6 2015-10-23
PCT/EP2016/075407 WO2017068140A1 (en) 2015-10-23 2016-10-21 Stem cell therapy based on adipose-derived stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022031113A Division JP2022084665A (ja) 2015-10-23 2022-03-01 脂肪由来幹細胞に基づく幹細胞治療

Publications (3)

Publication Number Publication Date
JP2018531269A true JP2018531269A (ja) 2018-10-25
JP2018531269A6 JP2018531269A6 (ja) 2018-12-13
JP2018531269A5 JP2018531269A5 (https=) 2019-11-28

Family

ID=54360137

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018520404A Pending JP2018531269A (ja) 2015-10-23 2016-10-21 脂肪由来幹細胞に基づく幹細胞治療
JP2022031113A Pending JP2022084665A (ja) 2015-10-23 2022-03-01 脂肪由来幹細胞に基づく幹細胞治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022031113A Pending JP2022084665A (ja) 2015-10-23 2022-03-01 脂肪由来幹細胞に基づく幹細胞治療

Country Status (13)

Country Link
US (2) US12433916B2 (https=)
EP (1) EP3365432B1 (https=)
JP (2) JP2018531269A (https=)
KR (1) KR20180063334A (https=)
CN (1) CN108135942A (https=)
AU (1) AU2016342387B2 (https=)
CA (1) CA3000912C (https=)
DK (1) DK3365432T3 (https=)
ES (1) ES2807897T3 (https=)
PL (1) PL3365432T3 (https=)
PT (1) PT3365432T (https=)
SI (1) SI3365432T1 (https=)
WO (1) WO2017068140A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112505C (en) 2018-09-20 2023-06-20 Citospin, S.L. Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same
EP3923959A1 (en) 2019-02-15 2021-12-22 Rigshospitalet Stem cell therapy for patients with salivary gland dysfunction
EP3923960A1 (en) 2019-02-15 2021-12-22 Rigshospitalet, Copenhagen University Hospital Stem cell therapy for lacrimal gland dysfunction
CN111269888B (zh) * 2020-03-24 2022-04-08 山东兴瑞生物科技有限公司 一种adipsin基因修饰的脂肪干细胞、制备方法及其应用
EP3909593A1 (en) 2020-05-15 2021-11-17 Rigshospitalet Stem cells for treating skin lesions
TWI825446B (zh) * 2020-08-14 2023-12-11 中國醫藥大學 醫藥組合物治療組織缺血狀況之用途
US12426594B2 (en) 2020-09-24 2025-09-30 Everest Medical Innovation GmbH Cryoprotective compositions and methods for protection of a surgical site during cryosurgery
US12453805B2 (en) 2020-09-24 2025-10-28 Everest Medical Innovation GmbH Cryoprotective compositions, surgical kits, and methods for protection of a surgical site during cryosurgery
CO2020012570A1 (es) 2020-10-08 2022-04-08 Inst Distrital De Ciencia Biotecnologia E Innovacion En Salud Idcbis Método de estimulación de células mesenquimales para inducir expresión de factores inmunomoduladores

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520290A (ja) * 1998-07-09 2002-07-09 バイオライフ・ソリュージョンズ・インコーポレイテッド 低温での細胞保存用の溶液におけるアポトーシスレギュレーターの含有

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492103B1 (en) * 2000-01-31 2002-12-10 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
ES2313805B1 (es) 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
TW200726474A (en) 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
US9598673B2 (en) 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
US20090304654A1 (en) * 2008-04-30 2009-12-10 Regents Of The University Of California Methods for isolating adipose-derived stem cells and therapeutic use thereof
CN102124098B (zh) * 2008-06-27 2014-03-12 博傲沃德株式会社 细胞及组织的冷冻保存用组合物
GB0822246D0 (en) 2008-12-05 2009-01-14 Reneuron Ltd Composition
KR101344719B1 (ko) * 2011-07-19 2013-12-26 한국과학기술연구원 응력을 가하여 줄기세포를 평활근세포로 분화시키는 방법 및 평활근세포를 함유하는 조직공학용 복합체
JP6435267B2 (ja) * 2012-11-08 2018-12-05 インジェネロン インコーポレイテッド 再生細胞の培養、保存、及び投与のための培地
CN103074298B (zh) * 2013-01-04 2015-10-21 冯文峰 一种人脂肪间充质干细胞库及其构建方法
WO2014203267A2 (en) * 2013-06-17 2014-12-24 Kasiak Research Pvt. Ltd. Method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells
CN104357382A (zh) 2014-10-08 2015-02-18 黑龙江天晴干细胞有限公司 人脂肪干细胞的获取方法及多级同种异体脂肪干细胞库的构建方法
CN108348555B (zh) * 2015-09-08 2022-07-08 赛尔爱迪尔私人有限公司 细胞扩增方法和治疗组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520290A (ja) * 1998-07-09 2002-07-09 バイオライフ・ソリュージョンズ・インコーポレイテッド 低温での細胞保存用の溶液におけるアポトーシスレギュレーターの含有

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GINIS, I. ET AL.: "Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic stor", TISSUE ENGINEERING. PART C, METHODS, vol. 18, no. 6, JPN6020046847, 2012, pages 453 - 463, ISSN: 0004630708 *
MIYAGI-SHIOHIRA, C. ET AL.: "Cryopreservation of Adipose-Derived Mesenchymal Stem Cells", CELL MEDICINE, vol. 8, JPN6020046845, 26 August 2015 (2015-08-26), pages 3 - 7, ISSN: 0004630706 *
OISHI K ET AL.: "Cryopreservation of mouse adipose tissue-derived stem/progenitor cells", CELL TRANSPLANTATION, vol. 17, JPN6020046848, 2008, pages 35 - 41, ISSN: 0004402015 *
YANEZ, R. ET AL.: "Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable f", STEM CELLS, vol. 24, no. 11, JPN6020046846, 2006, pages 2582 - 2591, ISSN: 0004630707 *
YONG, K.W. ET AL.: "Phenotypic and functional characterization of long-term cryopreserved human adipose-derived stem cel", SCIENTIFIC REPORTS, vol. 5, JPN6020046844, 15 April 2015 (2015-04-15), pages 9596, ISSN: 0004630705 *

Also Published As

Publication number Publication date
US20260007702A1 (en) 2026-01-08
JP2022084665A (ja) 2022-06-07
DK3365432T3 (en) 2020-07-27
CA3000912A1 (en) 2017-04-27
CN108135942A (zh) 2018-06-08
AU2016342387A1 (en) 2018-04-26
PT3365432T (pt) 2020-07-27
ES2807897T3 (es) 2021-02-24
WO2017068140A1 (en) 2017-04-27
PL3365432T3 (pl) 2020-09-21
KR20180063334A (ko) 2018-06-11
EP3365432B1 (en) 2020-05-06
AU2016342387B2 (en) 2021-12-09
SI3365432T1 (sl) 2020-08-31
US12433916B2 (en) 2025-10-07
EP3365432A1 (en) 2018-08-29
US20180325957A1 (en) 2018-11-15
CA3000912C (en) 2024-01-09

Similar Documents

Publication Publication Date Title
US20260007702A1 (en) Stem cell therapy based on adipose-derived stem cells
JP2018531269A6 (ja) 脂肪由来幹細胞に基づく幹細胞治療
JP5998265B2 (ja) トレハロース及びデキストラン含有哺乳動物細胞移植用溶液
Bieback et al. Clinical protocols for the isolation and expansion of mesenchymal stromal cells
JP5341059B2 (ja) 幹細胞懸濁液
AU2007247725B2 (en) Immune privileged and modulatory progenitor cells
US12564607B2 (en) Cell population comprising mesenchymal cells, pharmaceutical composition comprising the same, and method for producing the same
JP2022501322A (ja) 機能的な間葉系幹細胞の富化集団を得る方法、それによって得られる細胞、およびその細胞を含む組成物
Frank et al. Evaluation of reagents used to coat the hollow-fiber bioreactor membrane of the Quantum® Cell Expansion System for the culture of human mesenchymal stem cells
JP2017165757A (ja) 間葉系間質細胞集団およびそれを作成する方法
KR20210045443A (ko) 아카보즈 또는 스타키오스를 포함하는 포유동물 세포 보존용 액
JP5753874B2 (ja) 細胞生存率低下抑制剤
HK1259517B (en) Stem cell therapy based on adipose-derived stem cells
HK1259517A1 (en) Stem cell therapy based on adipose-derived stem cells
CN110840914B (zh) 细胞治疗剂用于缓解或改善血管病变的方法
Sari et al. A Proliferation and surface marker characterization of adipose stem cells after culture in various processed outdated platelet lysate containing media
RU2795621C2 (ru) Способ получения клеток из зубной пульпы
JP2023050921A (ja) 接着性幹細胞製剤の製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211102